[ad_1]
Sanofi Genzyme (Korea), a division of Sanofi Genzyme (Korea), announced that it would exchange information on various heart diseases and discuss the latest trends in treatment and research. The Sanofi Symposium on Cardiology was successfully held.
At the symposium on cardiology organized by Sanofi, Fabry disease, a rare inherited disorder characterized by cardiac ischemia and cardiac hypertrophy, is one of the major diseases. In addition, the Sanofi Group, including Plavix, Roberitto and Afrobel, has attempted to integrate the heart disease brand with an integrated approach to heart disease, including myocardial infarction, heart failure and hypertension. About 80 cardiologists participated in this two-day event and active discussions on the treatment and research of heart disease took place.
Professor Kim Woo-sik (Kyunghee University Hospital, Cardiovascular Center, Kyunghee University Hospital) presided over the Kyung Hee University Medical Center and had the most up-to-date knowledge of diagnosis and treatment of the disease. rare Fabry and antiplatelet therapy in chronic heart disease. It was illuminated.
The first symposium conference focused on the possibility of potential patients based on an badysis of genealogy, taking into account the inherited nature of Fabry disease. ▲ Professor Jung Wook Jin of Gakcheon University (Gil Hospital) In addition, a lecture on "Diagnosis of Fabry Disease and Rapid Treatment" given by Professor Hong Gru of Yonsei University ( Severance Hospital), followed by a lecture by Professor Chang Woo-jin of the Sungkyunkwan University Medical School (circulatory organ of Samsung Changwon Hospital) The optimal management strategy for antiplatelet agents has been presented.
On the 4th day of the protest, Professor Park Chang-gyu of Koryo Medical Center (Guro Hospital Cardiology Department) will be President and Professor Kim Hyun-soo of Koshin Medical University will discuss the management of hypertension badociated with specific diseases such as kidney failure, diabetes and heart failure. I did my first lecture. (ACS) Department of Cardiology of Dong-San Hospital of Keimyung University of Medicine and Professor Hong's "Low-density Lipoprotein (LDL-C) Optimal Management Method of Low-Protein Lipoprotein Cholesterol" Soon- Management of antiplatelet drugs in the management of phagocytosis.
"Sanofi strives to improve patient treatment and social awareness of portfolio-based diseases of various heart diseases ranging from hypertension to rare diseases such as Fabry disease," Park Hee-kyung said. I will always do my best to innovate treatment and create an optimal treatment environment with health professionals. "
Sanofi is an antiplatelet agent used in the prevention of cardiovascular diseases such as myocardial infarction, stroke and peripheral arterial disease, including Fabrice, an alternative to Fabry Disease, approved by the US Food and Drug Administration. Drug Administration (EMA). , Rabelito 4, the first Korean compound badociated with Irbesartan, a therapeutic agent of arterial hypertension linked to ARBs, and Atorvastatin, a statin-based treatment for the treatment of hyperlipidemia, and at Afro Bell, an antihypertensive.
<© 2018 메디파나뉴스, 무단 전재 및 배포금지>& # 39; The Korean Medical News Center & # 39; MEDIPANA NEWS
Source link
